Celltrion Pharm, Inc. (068760.KQ)
KRW 48700.0
(3.4%)
KRW 48700.0
(3.4%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 100.42 Billion KRW | 45.17% |
| 2022 | 69.17 Billion KRW | 8.28% |
| 2021 | 63.88 Billion KRW | 16.13% |
| 2020 | 55.01 Billion KRW | 66.2% |
| 2019 | 33.1 Billion KRW | -21.22% |
| 2018 | 42.01 Billion KRW | -35.6% |
| 2017 | 65.24 Billion KRW | -0.96% |
| 2016 | 65.87 Billion KRW | -10.67% |
| 2015 | 73.74 Billion KRW | 97024.46% |
| 2014 | 75.92 Million KRW | -7.76% |
| 2013 | 82.31 Million KRW | -2.44% |
| 2012 | 84.37 Million KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 124.49 Billion KRW | 12.65% |
| 2024 Q1 | 110.51 Billion KRW | 10.05% |
| 2023 Q4 | 100.42 Billion KRW | 6.89% |
| 2023 Q1 | 89.67 Billion KRW | 29.63% |
| 2023 Q2 | 79.75 Billion KRW | -11.06% |
| 2023 FY | 100.42 Billion KRW | 45.17% |
| 2023 Q3 | 93.94 Billion KRW | 17.79% |
| 2022 FY | 69.17 Billion KRW | 8.28% |
| 2022 Q3 | 64.69 Billion KRW | -4.09% |
| 2022 Q2 | 67.44 Billion KRW | -6.71% |
| 2022 Q1 | 72.3 Billion KRW | 13.17% |
| 2022 Q4 | 69.17 Billion KRW | 6.93% |
| 2021 Q3 | 62.08 Billion KRW | 30.42% |
| 2021 Q1 | 59.37 Billion KRW | 107821.39% |
| 2021 FY | 63.88 Billion KRW | 16.13% |
| 2021 Q4 | 63.88 Billion KRW | 2.91% |
| 2021 Q2 | 47.6 Billion KRW | -19.82% |
| 2020 FY | 55.01 Billion KRW | 66.2% |
| 2020 Q1 | 32.91 Million KRW | -0.57% |
| 2020 Q2 | 46.96 Million KRW | 42.68% |
| 2020 Q3 | 49.31 Million KRW | 5.02% |
| 2020 Q4 | 55.01 Million KRW | 11.55% |
| 2019 Q3 | 33.89 Million KRW | -12.1% |
| 2019 Q2 | 38.55 Million KRW | 4.64% |
| 2019 FY | 33.1 Billion KRW | -21.22% |
| 2019 Q1 | 36.84 Million KRW | -12.31% |
| 2019 Q4 | 33.1 Million KRW | -2.34% |
| 2018 Q2 | 61.73 Million KRW | -3.39% |
| 2018 Q1 | 63.9 Million KRW | -2.06% |
| 2018 FY | 42.01 Billion KRW | -35.6% |
| 2018 Q4 | 42.01 Million KRW | -20.52% |
| 2018 Q3 | 52.86 Million KRW | -14.37% |
| 2017 FY | 65.24 Billion KRW | -0.96% |
| 2017 Q1 | 80.47 Million KRW | 22.16% |
| 2017 Q3 | 76.84 Million KRW | -3.71% |
| 2017 Q2 | 79.8 Million KRW | -0.82% |
| 2017 Q4 | 65.24 Million KRW | -15.1% |
| 2016 FY | 65.87 Billion KRW | -10.67% |
| 2016 Q2 | 71.68 Million KRW | -1.43% |
| 2016 Q1 | 72.72 Million KRW | -1.37% |
| 2016 Q3 | 73.49 Million KRW | 2.53% |
| 2016 Q4 | 65.87 Million KRW | -10.37% |
| 2015 Q4 | 73.74 Million KRW | -2.0% |
| 2015 FY | 73.74 Billion KRW | 97024.46% |
| 2015 Q1 | 76.76 Million KRW | 1.1% |
| 2015 Q3 | 75.25 Million KRW | -1.43% |
| 2015 Q2 | 76.34 Million KRW | -0.55% |
| 2014 Q1 | 82.13 Million KRW | -0.21% |
| 2014 Q2 | 80.14 Million KRW | -2.43% |
| 2014 Q3 | 77.95 Million KRW | -2.73% |
| 2014 Q4 | 75.92 Million KRW | -2.6% |
| 2014 FY | 75.92 Million KRW | -7.76% |
| 2013 Q3 | 83.5 Million KRW | 0.82% |
| 2013 Q1 | 84.56 Million KRW | 0.23% |
| 2013 Q2 | 82.82 Million KRW | -2.05% |
| 2013 Q4 | 82.31 Million KRW | -1.43% |
| 2013 FY | 82.31 Million KRW | -2.44% |
| 2012 Q4 | 84.37 Million KRW | 0.0% |
| 2012 FY | 84.37 Million KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 20.85 Billion KRW | -381.447% |
| CMG Pharmaceutical Co., Ltd. | 15.87 Billion KRW | -532.541% |
| Huons Global Co., Ltd. | 121.81 Billion KRW | 17.565% |
| DongKook Pharmaceutical Co., Ltd. | 138.34 Billion KRW | 27.412% |
| Enzychem Lifesciences Corporation | 14.94 Billion KRW | -571.897% |
| Humedix Co., Ltd. | 28.62 Billion KRW | -250.811% |
| Boditech Med Inc. | 31.6 Billion KRW | -217.757% |
| EuBiologics Co., Ltd. | 13.34 Billion KRW | -652.693% |
| FutureChem Co.,Ltd | 1.37 Billion KRW | -7205.959% |
| Huons Co., Ltd. | 76.59 Billion KRW | -31.101% |
| BNC Korea Co., Ltd. | 11.39 Billion KRW | -781.388% |
| AptaBio Therapeutics Inc. | - KRW | -Infinity% |